Use of Radium-223
Scottish Cancer Network: Clinical Management Pathways
Warning
Radium-223 is indicated and SMC approved for:
Monotherapy or in combination with LHRH analogue for adult patients with mCRPC, symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment.
Radium-223 can be considered at any point in the CRPC pathway.
Use of radium-223 should be considered when prior ARPI/chemotherapy options have been exhausted, or where patients are ineligible or unsuitable for systemic treatment.
Patients should be commenced on a bisphosphonate before commencing radium-223.
See supportive care section of CMP for advice on bone health.
See supportive care section of CMP for advice on bone health.
